Fall 2025

Intern – R&D Engineering Operations: June

Posted on 3/18/2025

Insulet Corporation

Insulet Corporation

1,001-5,000 employees

Develops tubeless insulin delivery systems

Compensation Overview

$23 - $27.50/hr

San Diego, CA, USA

Category
Mobile Engineering
Software QA & Testing
Software Engineering
Connection
Connection
Connection
logo

Get referrals →

You have ways to get a Insulet Corporation referral from your network.

💡

Applications through a referral are 3x more likely to get an interview!

Requirements
  • Working towards BS in Software Engineering, Computer Science, Electronics, or similar field.
  • Experience communicating in a friendly manner with individuals at all levels, both externally and internally within the organization is required.
Responsibilities
  • Be first point of contact for lab support requests, in-person and via chat.
  • Support implementation and validation of Test Automation tool infrastructure.
  • Distribute devices for internal employee use.
  • Troubleshoot, upgrade, and maintain mobile device farm within the lab.
  • Develop and maintain documentation for the mobile device farm, including user procedures.
  • Maintain the lab/storage spaces in a clean, organized, and uncluttered way.
  • Coordinate purchase orders and requests for lab equipment, as necessary.
Desired Qualifications
  • Demonstrated success in utilizing advanced Python scripting/automation knowledge and willingness to build something from scratch
  • Excellent verbal and written communication skills
  • Ability to manage multiple tasks and prioritize work accordingly.
  • Excellent teamwork/problem solving skills and a positive attitude.
  • Dependable, highly organized, and very detail oriented.
  • Ability to act independently and use discretionary judgment.
  • Proven troubleshooting and analytical skills

Insulet Corporation focuses on creating medical devices that make life easier for individuals with diabetes and other health conditions. Their main product, the Omnipod Insulin Management System, offers a different approach to insulin delivery compared to traditional methods. The Omnipod is a tubeless, disposable device that can deliver insulin continuously for up to three days without the need for needles. A key feature of the Omnipod 5 Automated Insulin Delivery System is its ability to work with a continuous glucose monitor, allowing users to manage their blood sugar levels without daily injections or fingersticks. This system can be controlled via a smartphone or a dedicated controller. Insulet stands out from competitors by providing a simple, wearable solution that eliminates the hassle of traditional insulin delivery methods. The company's goal is to improve the quality of life for people with diabetes by offering convenient and effective insulin management solutions.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Acton, Massachusetts

Founded

2000

Simplify Jobs

Simplify's Take

What believers are saying

  • Growing demand for advanced diabetes solutions expands Insulet's market opportunities.
  • Omnipod 5's European expansion increases Insulet's international market presence.
  • Advancements in sensor technology enhance the reliability of Insulet's Omnipod system.

What critics are saying

  • Leadership transition to Ashley McEvoy may lead to strategic instability.
  • Increased competition from DexCom and Tandem Diabetes Care challenges Insulet's market share.
  • Potential financial strain from $450M senior notes offering could impact cash flow.

What makes Insulet Corporation unique

  • Insulet's Omnipod 5 integrates with Dexcom G7 CGM, enhancing diabetes management.
  • The RADIANT trial showcases Insulet's innovation in transitioning from daily injections to Omnipod.
  • Insulet's $452M trade secret victory strengthens its competitive position in insulin pump technology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
RTTNews
Apr 28th, 2025
Insulet CEO Jim Hollingshead Resigns, Ashley McEvoy To Succeed; Raises Q1 Guidance

Insulet Corp. (PODD), a medical device company, on Monday announced that Chief Executive Officer Jim Hollingshead has resigned from the Board of Directors.

MD+DI
Apr 28th, 2025
Insulet Names Ex-J&J MedTech Chief Ashley McEvoy as CEO

Ashley McEvoy has been tapped to be president and CEO of Insulet.

Financial Modeling Prep
Mar 28th, 2025
Insulet Corporation's Financial Efficiency in the Medical Device Industry

Insulet competes with companies like DexCom, Tandem Diabetes Care, and Masimo Corporation in the diabetes care market.

Stock Titan
Mar 18th, 2025
Insulet Secures $450M Through Senior Notes Offering: Key Details on Strategic Debt Refinancing

Insulet raises $444.4M through senior notes to refinance existing convertible debt. Strategic move positions medical device maker for future growth while optimizing capital structure.

Stock Titan
Mar 18th, 2025
From Injections to Innovation - Insulet to Present Results from a Multinational Randomized Trial of Direct Transition from Multiple Daily Injections to Omnipod(R) 5 in Adults and Children with Type 1 Diabetes

Insulet (NASDAQ: PODD) will present results from its multinational RADIANT trial at the 18th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in March 2025.

INACTIVE